MeSH term
Frequency | Condition_Probility | Albuminuria/*urine | 2 | 16.0 |
Biological Markers/urine | 2 | 3.0 |
Female | 21 | 0.0 |
Humans | 41 | 0.0 |
Male | 21 | 0.0 |
Middle Aged | 14 | 0.0 |
Research Support, Non-U.S. Gov't | 17 | 0.0 |
Risk Factors | 3 | 0.0 |
Blood Pressure | 3 | 0.0 |
Body Mass Index | 2 | 0.0 |
Cohort Studies | 2 | 0.0 |
Creatinine/urine | 4 | 3.0 |
Time Factors | 3 | 0.0 |
Animals | 12 | 0.0 |
Conserved Sequence | 2 | 0.0 |
Mutation | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 8 | 0.0 |
Adult | 13 | 0.0 |
Aged | 10 | 0.0 |
Biological Markers | 2 | 0.0 |
Prospective Studies | 3 | 0.0 |
Comparative Study | 9 | 0.0 |
Reproducibility of Results | 3 | 0.0 |
Acute Disease | 4 | 0.0 |
Mice | 6 | 0.0 |
Mice, Inbred C3H | 2 | 0.0 |
Blood Glucose/metabolism | 2 | 0.0 |
Hemoglobin A, Glycosylated/analysis | 2 | 0.0 |
Cells, Cultured | 5 | 0.0 |
English Abstract | 6 | 0.0 |
Infusions, Intravenous | 2 | 0.0 |
Gene Library | 2 | 0.0 |
Molecular Sequence Data | 2 | 0.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Adolescent | 2 | 0.0 |
Child | 2 | 0.0 |
Acrosin/*genetics | 2 | 100.0 |
Enzyme Precursors/*genetics | 2 | 1.0 |
Antineoplastic Agents/*therapeutic use | 2 | 0.0 |
Cell Division | 2 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
*Chromosomes, Human, Pair 22 | 2 | 0.0 |
DNA Probes | 2 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Receptors, Androgen/*analysis | 2 | 3.0 |
Naphthacenes/therapeutic use | 2 | 100.0 |
Rats | 2 | 0.0 |
Intestinal Polyps/*genetics | 2 | 18.0 |
